The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
 
Jiayu Wang
No Relationships to Disclose
 
Binghe Xu
No Relationships to Disclose
 
Wenxiang Wang
Employment - RemeGen
Stock and Other Ownership Interests - RemeGen
Honoraria - RemeGen
Research Funding - RemeGen
Travel, Accommodations, Expenses - RemeGen
 
Jianmin Fang
Employment - RemeGen
Leadership - RemeGen
Stock and Other Ownership Interests - RemeGen
Honoraria - RemeGen
Speakers' Bureau - RemeGen
Research Funding - RemeGen
Patents, Royalties, Other Intellectual Property - RemeGen Ltd
Expert Testimony - RemeGen
Travel, Accommodations, Expenses - RemeGen